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Available online 18 October 2010If sarcoidosis were a granulomatous response to an
elusive, poorly degradable, non-virulent antigen(s),
entailing an unpredictable risk of lethal pulmonary
fibrosis, then corticosteroid (CS) intervention would be
intuitively justifiable. Its benefit would be clearly evident
in controlled trials of acute disease and among inten-
sively treated individuals in tertiary care centers. If, on
the other hand, the systemic granulomas are a default
response (tending to spontaneous resolution) to diverse
antigens in persons with demonstrable impairment in
cellular immune response, withholding CS suppression
during the early (Th1) response would be the rational
decision, and would be evident in the same circum-
stances. Experimental evidence and clinical experience,
both delineated in the MS, favor the latter view: Treated
under the former premise, sarcoidosis mortality has been
an order of magnitude higher than under the latter.
Confining intervention to individuals with chronic,
progressive, pulmonary shadowing conforms to current
UK,1 ATS, ERS and WASOG guidelines.2DOI of original article: 10.1016/j.rmed.2010.07.001.
* Associate Editor, Dr. Marc A. Judson refereed this debate. He
edited this debate for purposes of internal consistency; these edits
did not significantly affect the debate’s content.
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my rebuttal will be confined to germane datadinformation
on the long-term outcome in persons with recent-onset
pulmonary shadowing treated with systemic CS. It will
exclude a priori statements, unattested allegations of effi-
cacy and articles lacking new data (Culver 2,14, 17), uncon-
trolled studies or those lacking long-term follow-up
(C1,6,8,11,22,23,24), stage I data (themajority in C6), other
treatments including inhaled CSdwhich is no longer recom-
mended (C10,18,26), other diseases (C15,16,28,32,33,34,35)
and non-treatment aspects of sarcoidosis (C21,29,31,32).
Dr. Culver instances not a single example of long-term
benefit of CS in controlled trials of acute pulmonary sarcoid-
osis, nor a response to the far higher mortality reported in
tertiary care centers that more frequently prescribe CS. The
majority of germane studies advanced in support of his
viewpoint are delineated in pre´cis in a systematic review3:
C4 Zaki: Poor compliance with treatment and follow-up
studies invalidates this study.3
C5 Israel: Our interpretations differ. In those with pulmo-
nary shadowing the authors reported definite improvement
(in a combined radiographic, FVC and corticosteroid require-
ment assessment) on long-term evaluation in 48% of treated
vs. 44% of controls; progression in 38% of treated vs. 16% of
controls; normal CXR attained in 6 treated vs. 10 controls.
Allocation was unspecified for the 2 sarcoidosis deaths.3
C7 Selroos: enrolled persons with pulmonary shadowing
of 5-years duration. There was no long-term evidence of.
The treatment of the granulomatous response 1783either benefit or harm in this small, controlled trial,
consistent with other trials in persons with disease of
intermediate duration.3
C8 Johns: Uncontrolled. Usual policy was to avoid CS
within first two years (allowing for spontaneous improve-
ment) in the absence of compelling symptoms.
C9 Eule: Untreated controls fared better than CS recip-
ients. See review.3
C19 Paramothayan: Limitations addressed both in the MS
and the review.3
C20 Gibson: Limitations addressed both in the MS and
the review.3
To the question “.why wouldn’t you treat a patient
with acute sarcoidosis?” I answer: 1) Many improve/resolve
spontaneously. 2) Avoidance of CS side effects. 3) Persua-
sive evidence that CS impairs resolution, leading to much
higher mortality vs. conservative management.Conflict of interest
None.
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